Send to

Choose Destination
J Mol Neurosci. 2016 Nov;60(3):362-370. Epub 2016 Sep 1.

Performance on the Cogstate Brief Battery Is Related to Amyloid Levels and Hippocampal Volume in Very Mild Dementia.

Author information

The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, 155 Oak Street, Parkville, VIC, 3052, Australia.
The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, 155 Oak Street, Parkville, VIC, 3052, Australia.
Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, VIC, Australia.
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, VIC, Australia.
Centre of Excellence for Alzheimer's Disease Research and Care, Edith Cowan University, Joondalup, WA, Australia.
Sir James McCusker Alzheimer's Disease Research Unit, Hollywood Private Hospital, Perth, WA, Australia.
Co-operative Research Centre for Mental Health, Carlton, Australia.
Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
Academic Unit for Psychiatry of Old Age, St. Vincent's Health, The University of Melbourne, Kew, VIC, Australia.
National Ageing Research Institute, Parkville, VIC, Australia.
Department of Neurology, Alpert Medical School of Brown University, Providence, RI, USA.
Commonwealth Scientific Industrial Research Organization (CSIRO) Preventative Health National Research Flagship, Australian e-Health Research Centre-BiaMedIA, Brisbane, QLD, Australia.
CogState Ltd., Melbourne, VIC, Australia.


In a group of older adults with very mild dementia, we aimed to characterize the nature and magnitude of cognitive decline as measured by the Cogstate Brief Battery, in relation to Aβ levels and hippocampal volume. Participants were characterized according to their status on the Clinical Dementia Rating (CDR) scale. A total of 308 individuals who were CDR 0 and had low cerebral Aβ levels (Aβ-), 32 individuals who were Aβ- and CDR 0.5, and 43 individuals who were Aβ+ and CDR 0.5 were included in this study. Participants completed the CogState brief battery at baseline, and at 18-, 36-, 54- and 72-month follow-up. Linear mixed model analyses indicated that relative to the Aβ- CDR 0 group, the Aβ+ CDR 0.5 group showed increased rates of memory decline and hippocampal volume loss. However, compared to the Aβ- CDR 0 group, the Aβ- CDR 0.5 group showed no changes in cognitive function or hippocampal volume over 72 months. The results of this study confirm that in individuals with very mild dementia, who also have biomarker confirmation of Aβ+, changes in cognitive function manifest primarily as deterioration in memory processing, and this is associated with hippocampal volume loss. Conversely, the absence of any cognitive decline or loss in hippocampal volume in individuals with very mild dementia but who are Aβ- suggests that some other non-AD disease process may underlie any static impairment in cognitive function.


Alzheimer’s disease; Amyloid; Hippocampal volume; Memory; Mild dementia

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center